Healthcare Industry News: DePuy
News Release - September 5, 2008
Axial Biotech appoints new Vice President of Strategic InitiativesIndustry Veteran is Well-Positioned to Expand Business Development Efforts
SALT LAKE CITY, Sept. 5 (HSMN NewsFeed) -- Axial Biotech Inc., a company focused on the development of molecular diagnostic and motion preserving technologies in the spine care market, announced today that Joe Ross has joined the executive management team as the company's new Vice President of Strategic Initiatives.
In this new role, Ross will oversee Axial Biotech's global efforts to identify, evaluate, and pursue new diagnostic opportunities and will help to coordinate the company's long-term business strategy, solicit investment backing, and expand key development partnerships.
John Climaco, President and CEO of Axial Biotech, stated, "As we prepare for the commercial introduction of our DNA based prognostic test for Adolescent Idiopathic Scoliosis with our partners at DePuy Spine, we look forward to building on our successful research, and developing additional diagnostic tools to meet the clinical needs of today, and those anticipated in the future. Mr. Ross is uniquely qualified to drive this effort given his vast industry knowledge and experience, and successful track record of working closely with physician thought leaders to develop innovative clinical solutions."
Ross brings with him more than 12 years of experience in orthopedic medical devices and biologics. Prior to his most recent position as Vice President of Global Marketing for Stryker Biotech, Ross worked 11 years with the DePuy Spine division of Johnson and Johnson Corporation in roles of increasing responsibility including Worldwide Vice President for New Business Development. Ross has led numerous successful product and business development efforts and has been granted multiple U.S. patents. He is a graduate of the University of Notre Dame and Troy State University. He has also served five years as an officer in the United States Navy.
"I am thrilled to be joining the Axial Biotech team of accomplished researchers, clinicians and business professionals," said Ross. "The technologies being developed by Axial Biotech have the potential to transform not only the diagnostic process, but the identification and timing of the appropriate therapy, and ultimately to drive the development of revolutionary new treatments for multiple diseases of the spine. This is transformational technology that will significantly enhance patient outcomes and quality of life."
About Axial Biotech
Axial Biotech, Inc. develops molecular diagnostic assays and motion preservation technologies for common spinal diseases and disorders. Axial has developed the first DNA based prognostic test for Adolescent Idiopathic Scoliosis. Axial is accredited by the College of American Pathologists (CAP) and is certified to comply with the Clinical Laboratory Improvement Amendments (CLIA). Founded in 2002, Axial is based in Salt Lake City, Utah.
Source: Axial Biotech
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.